Safety Study of MPD-1 for Advanced Solid Tumors
Part of Cancer clinical trials.
This trial tests a new drug called MPD-1 for people with advanced solid tumors that have not responded to standard treatments. It focuses on patients with specific genetic changes (KRAS mutation or PTEN loss) to see if the drug is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 75 years old.
- You have advanced solid tumor that has spread or cannot be removed, and standard treatments no longer work or were not enough.
- Your tumor has a KRAS mutation or PTEN loss, confirmed by a lab test before screening.
- You have never taken anthracycline or anthracene drugs (a type of chemotherapy).
- You have at least one tumor that can be measured or assessed on scans.
- Your blood counts, kidney, and liver function are within certain acceptable ranges (specific tests will be done).
- Your overall health is good (ECOG score 0 or 1), and you are expected to live at least 12 more weeks.
- You have recovered from side effects of previous treatments (except hair loss or mild nerve issues).
- You agree to use effective contraception if you or your partner could become pregnant, for at least 24 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This Phase 1 trial tests how safe PMC-309 is and how the drug behaves in the body (blood levels) in people with advanced or metastatic solid tumors. Because it’s an early study, the main goal is to find safe dosing and gather information that could guide future treatments.
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This study tests a new medicine called IPN01195 for adults with advanced solid tumors that have a specific genetic change (MAPK pathway). It aims to see if the drug is safe and works against these cancers when other treatments are no longer working.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.